Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate

Clinical and Experimental Immunology

Volumn 126, Issue 1, 2001, Pages 16-28

  Goddard, Ruth Victoria ^a   Prentice, A G ^a   Copplestone, J A ^a   Kaminski, E R ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

B cell chronic lymphocytic leukaemia; Dendritic cells; HLA class II; Lysate; Tumour

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL LYSATE; CELL POPULATION; CELL PROLIFERATION; CELL STIMULATION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHATIC LEUKEMIA; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL EXTRACTS; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; KINETICS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034781930     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01617.x     Document Type: Article

References (67)

1. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia
2. Chronic lymphocytic leukaemia
3. One hundred years of cancer immunology: A critical appraisal
4. Cells and cytokines in immunotherapy and gene therapy of cancer
5. Dendritic cells and the control of immunity
6. The biology and clinical applications of dendritic cells
7. Dendritic cell maturation and generation of immune responses
8. Why are dendritic cells central to cancer immunotherapy?
9. Dendritic cells: Development, function and potential use for cancer immunotherapy
10. Dendritic cell-based vaccine: A promising approach for cancer immunotherapy
11. Dendritic cell vaccines for cancer immunotherapy
12. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability
13. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4 and tumor necrosis factor-α for use in cancer immunotherapy
14. Generation of anti-melanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-driven epitopes by dendritic cells in vitro
15. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A /MART-1 self antigen
16. Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognise unidentified shared melanoma antigens
17. Use of leukemic dendritic cells for the generation of anti-leukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia
18. Dendritic cells generated from blood precursors of chronic myelogenous leukaemia patients carry the translocation and can induce a CML-specific primary cytotoxic T-cell response
19. Dendritic cells stimulate the expansion of bcr-abl specific CD8 + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia
20. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
21. Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells
22. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
23. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells
24. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
25. Dendritic cell immunotherapy in disseminated parathyroid carcinoma
26. Phase I clinical trial: T-cell therapy for prostrate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostrate-specific membrane antigen
27. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
28. Follow-up evaluation of Phase II prostate cancer vaccine trial
29. + blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer
30. Immunofluorescence of surface markers
31. Analysing cytotoxic T lymphocyte activity: A simple and reliable flow cytometry-based assay
32. Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumours
33. Tumour-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkins lymphoma
34. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long term results of a clinical trial
35. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
36. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
37. Stimulationof cytotoxicT cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
38. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
39. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those produced from healthy donors
40. Cutting edge: Dendritic cells require maturation via CD40 to generate protective anti-tumor immunity
41. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukaemia B cells
42. The role of B7.1/B7.2: CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response
43. Dendritic cells as adjuvants for immune-mediated resistance to tumours
44. Impediments to successful immunotherapy
45. Effects of TGF-β on the immune system: Implications for cancer immunotherapy
46. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
47. + T cells resulting in a failure to lyse tumor cells
48. Dysregulation of T lymphocyte activation markers in B-cell chronic lymphocytic leukaemia
49. T cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal
50. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the TH1-biasing cytokines IL-12 and IFN-α
51. Stimulatory and inhibitory differentiation of human myeloid dendritic cells
52. + lymphocytes in the initiation of class-I-restricted reactivity to a tumor/self peptide
53. IL-12 responsiveness and expression of IL-12 receptor in human peripheral blood monocyte derived dendritic cells
54. Human dendritic cells require exogenous Interleukin-12-inducing factors to direct the development of naïve T-helper cells toward the Th1 phenotype
55. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells
56. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells
57. Bone-marrow-derived dendritic cells pulsed with synthetic peptides elicit protective and therapeutic antitumour immunity
58. Generation of primary peptide-specific CD8+ve cytotoxic T lymphocytes in vitro using allogeneic dendritic cells
59. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses
60. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo
61. Cancer vaccines
62. CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma
63. Cytotoxic CD4+ and CD8+ T lymphocytes generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognise 12Val-dependant nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation
64. Effects on human peripheral lymphocytes of in vivo administration of 9-b-d- arabinofur-anosyl-2-fluroadenosine-5′monophosphate (NSC 312887), a new purine anti-metabolite
65. Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells
66. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia
67. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease